Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RNF4 | P78317 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311835 | 0.82 | SMN1; SMN2 (0.66) | FAAHSMN1; SMN2PDGFRB | |
| SCHEMBL3026001 | 0.80 | FAAH (0.67) | FAAH | |
| SCHEMBL28363630 | 0.79 | EPHX2 (0.67) | FAAHSMN1; SMN2HPGDPDGFRBRECQL | |
| SCHEMBL4676020 | 0.78 | POLB (0.73) | FAAHSMN1; SMN2HPGDPGRPDGFRB | |
| SCHEMBL20236423 | 0.78 | FAAH (0.61) | FAAHSMN1; SMN2HPGDPGRPDGFRB | |
| SCHEMBL4676015 | 0.78 | FAAH (0.61) | FAAHPDGFRB | |
| SCHEMBL28363634 | 0.78 | NPC1 (0.65) | FAAHGRIN2BSMN1; SMN2HPGDNAMPT | |
| SCHEMBL9467061 | 0.77 | MAPT (0.74) | FAAHSMN1; SMN2PDGFRB | |
| SCHEMBL22218259 | 0.77 | FAAH (0.60) | FAAHSMN1; SMN2HPGDPDGFRBNPY5R | |
| SCHEMBL3314993 | 0.77 | GRIN2B (0.48) | FAAHGRIN2BSMN1; SMN2HPGDPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | FAAH 637/4885GRIN2B 135/4885SMN1; SMN2 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.